Notably, this study may provide strong scientific evidence to establish the ARAF p.S214C mutation as a novel biomarker for predicting sorafenib’s efficacy in lung cancer and inform future clinical trials aiming to evaluate the sorafenib responses in ARAF-mutated lung cancer patients. Here, ARAF is linked to lung carcinoma.